Focus: HeartFlow is a public biotech company specializing in AI-enabled coronary artery disease diagnostics, primarily through its flagship FFRCT imaging technology. The company operates at the intersection of cardiovascular imaging and computational diagnostics, serving a focused but critical cardiac care market.
Profile data last refreshed 10h ago · AI intelligence enriched 1w ago
Hot — 264 jobs added in 30d
Net +241 (264 new, 23 removed). Aggressive expansion phase.
HeartFlow suits early-to-mid-career professionals in software engineering, clinical data science, and commercial roles seeking a focused, well-funded diagnostic AI company, but offers limited opportunity for traditional pharma/biotech development specialists.
Help build intelligence for HeartFlow
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from HeartFlow's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), HeartFlow, Inc. (HTFL) and Neurogene (NGNE) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), HeartFlow, Inc. (HTFL) and Neurogene (NGNE) The Globe and Mail
Is HeartFlow Stock a Buy After an Institutional Investor Initiated a Position Worth $2.7 Million? - The Motley Fool
Is HeartFlow Stock a Buy After an Institutional Investor Initiated a Position Worth $2.7 Million? The Motley Fool
Heartflow's Q1 2026 Beat: Is This the Turning Point for HTFL - Kavout
Heartflow's Q1 2026 Beat: Is This the Turning Point for HTFL Kavout
Imaging-Based FFR on Par With Wire for PCI Outcomes - MedPage Today
Imaging-Based FFR on Par With Wire for PCI Outcomes MedPage Today
A new clinical trial based on imaging diagnostics could bring a novel approach to the use of cholesterol-lowering drugs - Semmelweis Egyetem
A new clinical trial based on imaging diagnostics could bring a novel approach to the use of cholesterol-lowering drugs Semmelweis Egyetem
8-K Filing: Heartflow, Inc. (HTFL) (CIK 0001464521) — EX-99.1
EX-99.1
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Artificial intelligence-enabled coronary plaque quantification for personalized risk assessment and lipid-lowering therapy: Insights from the FISH&CHIPS study(✰).
Coronary Atherosclerosis in Former NFL Players: A Case Series From the GAMEFILM Registry.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo